NeoGenomics reported a 10% revenue increase for the second quarter driven by clinical testing growth but slashed full-year revenue and earnings forecasts following delays and challenges in biopharmaceutical business and liquid biopsy product launches. Despite higher test volume in next-generation sequencing assays, commercial setbacks and asset impairments negatively impacted profitability, with net losses widening compared to prior-year quarters. The company plans to enhance R&D for therapy selection and minimal residual disease products while expanding its sales and partnerships.